Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1102-1111
Published online before print March 24, 2005, doi: 10.1161/01.ATV.0000163262.83456.6d
Published online before print March 24, 2005, doi: 10.1161/01.ATV.0000163262.83456.6d
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Brief Reviews |
Myeloperoxidase and Cardiovascular Disease
From the Departments of Cardiovascular Medicine and Cell Biology and Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic Foundation, Cleveland, Ohio.
Correspondence to Stanley L. Hazen, MD, PhD, Cleveland Clinic Foundation, Lerner Research Institute, Center for Cardiovascular Diagnostics and Prevention, 9500 Euclid Avenue, NC-10, Cleveland, OH 44195. E-mail hazens{at}ccf.org
Series Editor: Kathy K. Griendling
Redox Mechanisms in Blood Vessels
ATVB in Focus
Previous Brief Reviews in this Series:
•Mueller CFH, Laude K, McNally JS, Harrison DG. Redox mechanisms in blood vessels. 2005;25:274–278.
•Gutterman DD, Miura H, Liu Y. Redox modulation of vascular tone: focus of potassium channel mechanisms of dilation. 2005;25:671–678.
Myeloperoxidase (MPO) is a leukocyte-derived enzyme that catalyzes the formation of a number of reactive oxidant species. In addition to being an integral component of the innate immune response, evidence has emerged that MPO-derived oxidants contribute to tissue damage during inflammation. MPO-catalyzed reactions have been attributed to potentially proatherogenic biological activities throughout the evolution of cardiovascular disease, including during initiation, propagation, and acute complication phases of the atherosclerotic process. As a result, MPO and its downstream inflammatory pathways represent attractive targets for both prognostication and therapeutic intervention in the prophylaxis of atherosclerotic cardiovascular disease.
Myeloperoxidase-catalyzed reactions have been attributed to potentially proatherogenic biological activities throughout the evolution of cardiovascular disease, including during initiation, propagation, and acute complication phases of the atherosclerotic process. As a result, myeloperoxidase and its downstream inflammatory pathways represent attractive targets for both prognostication and therapeutic intervention in the prophylaxis of atherosclerotic cardiovascular disease.
Key Words: atherosclerosis • free radical • heart failure • high-density lipoprotein • low-density lipoprotein • myeloperoxidase • nitric oxide • scavenger receptor • vulnerable plaque
This article has been cited by other articles:
 |
|
 |
|
  D. El Kebir, L. Jozsef, W. Pan, and J. G. Filep Myeloperoxidase Delays Neutrophil Apoptosis Through CD11b/CD18 Integrins and Prolongs Inflammation Circ. Res., August 15, 2008; 103(4): 352 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Vaz and O. Augusto Reactive Oxygen Species Special Feature: Inhibition of myeloperoxidase-mediated protein nitration by tempol: Kinetics, mechanism, and implications PNAS, June 17, 2008; 105(24): 8191 - 8196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18 Eur. Heart J., May 1, 2008; 29(9): 1096 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Salvarani, B Casali, E Farnetti, N Pipitone, D Nicoli, P L Macchioni, L Cimino, G L Bajocchi, M G Catanoso, L Pattacini, et al. -463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis Ann Rheum Dis, April 1, 2008; 67(4): 485 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Leeuwen, M. J.J. Gijbels, A. Duijvestijn, M. Smook, M. J. van de Gaar, P. Heeringa, M. P.J. de Winther, and J. W. C. Tervaert Accumulation of Myeloperoxidase-Positive Neutrophils in Atherosclerotic Lesions in LDLR / Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 84 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Rector, S. O. Warner, Y. Liu, P. S. Hinton, G. Y. Sun, R. H. Cox, C. S. Stump, M. H. Laughlin, K. C. Dellsperger, and T. R. Thomas Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E500 - E506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Meuwese, E. S.G. Stroes, S. L. Hazen, J. N. van Miert, J. A. Kuivenhoven, R. G. Schaub, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, et al. Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals: The EPIC-Norfolk Prospective Population Study J. Am. Coll. Cardiol., July 10, 2007; 50(2): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang, W. Tong, R. W. Troughton, M. G. Martin, K. Shrestha, A. Borowski, S. Jasper, S. L. Hazen, and A. L. Klein Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2364 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Gharavi, P. S. Gargalovic, I. Chang, J. A. Araujo, M. J. Clark, W. L. Szeto, A. D. Watson, A. J. Lusis, and J. A. Berliner High-Density Lipoprotein Modulates Oxidized Phospholipid Signaling in Human Endothelial Cells From Proinflammatory to Anti-inflammatory Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1346 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow Appraisal of Myeloperoxidase for Evaluation of Patients With Suspected Acute Coronary Syndromes J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2001 - 2002. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Mocatta, A. P. Pilbrow, V. A. Cameron, R. Senthilmohan, C. M. Frampton, A. M. Richards, and C. C. Winterbourn Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction J. Am. Coll. Cardiol., May 22, 2007; 49(20): 1993 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Altwegg, M. Neidhart, M. Hersberger, S. Muller, F. R. Eberli, R. Corti, M. Roffi, G. Sutsch, S. Gay, A. von Eckardstein, et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes Eur. Heart J., April 12, 2007; (2007) ehm078v3. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Borawski, B. Naumnik, and M. Mysliwiec Heparin, Myeloperoxidase, and Atherosclerosis: A New Focus on an Old Drug Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 219 - 220. [PDF]
|
|
|
|
|
|
W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-G. Wang, S. A. Mahmud, J. Nguyen, and A. Slungaard Thiocyanate-Dependent Induction of Endothelial Cell Adhesion Molecule Expression by Phagocyte Peroxidases: A Novel HOSCN-Specific Oxidant Mechanism to Amplify Inflammation J. Immunol., December 15, 2006; 177(12): 8714 - 8722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Rabelink and A.-J. van Zonneveld Coupling eNOS Uncoupling to the Innate Immune Response. Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2585 - 2587. [Full Text] [PDF]
|
|
|
|
|
|
C. Cuccurullo, A. Iezzi, M. L. Fazia, D. De Cesare, A. Di Francesco, R. Muraro, R. Bei, S. Ucchino, F. Spigonardo, F. Chiarelli, et al. Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2716 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, Y. Cheng, R. Ji, and C. Zhang Novel model of inflammatory neointima formation reveals a potential role of myeloperoxidase in neointimal hyperplasia Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3087 - H3093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S I van Leuven, J J P Kastelein, M R Hayden, and E S Stroes Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis? Lupus, November 1, 2006; 15(11_suppl): 11 - 17. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Yang, R. Ji, Y. Cheng, J.-Z. Sun, L. K. Jennings, and C. Zhang L-Arginine Chlorination Results in the Formation of a Nonselective Nitric-Oxide Synthase Inhibitor J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1044 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Chen, M. Querol Sans, A. Bogdanov Jr, and R. Weissleder Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology, August 1, 2006; 240(2): 473 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Jaffer, P. Libby, and R. Weissleder Molecular and Cellular Imaging of Atherosclerosis: Emerging Applications J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1328 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hartung, M. Sarai, A. Petrov, F. Kolodgie, N. Narula, J. Verjans, R. Virmani, C. Reutelingsperger, L. Hofstra, and J. Narula Resolution of Apoptosis in Atherosclerotic Plaque by Dietary Modification and Statin Therapy J. Nucl. Med., December 1, 2005; 46(12): 2051 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ou, J. Wang, H. Xu, Z. Ou, M. G. Sorci-Thomas, D. W. Jones, P. Signorino, J. C. Densmore, S. Kaul, K. T. Oldham, et al. Effects of D-4F on Vasodilation and Vessel Wall Thickness in Hypercholesterolemic LDL Receptor-Null and LDL Receptor/Apolipoprotein A-I Double-Knockout Mice on Western Diet Circ. Res., November 25, 2005; 97(11): 1190 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow High-Density Lipoprotein Function: Recent Advances J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1792 - 1798. [Abstract] [Full Text] [PDF]
|
|